Deals this week: Hutchison China Meditech, EastGate Biotech, Tocagen
Hong Kong-based biopharmaceutical company Hutchison China Meditech intends to raise funds by issuing American Depository Shares in a public offering.
The proceeds are intended to be used for general corporate purposes.
EastGate Biotech and AC Nova Technologies have formed a joint venture (JV) to commercialise evidence-based natural therapies focused on glucose balance and cardiovascular health, enabling them to provide complementary therapies to slow down aging symptoms.
Both companies involved in the JV are based in Canada.
US-based pharmaceutical company Tocagen has announced that it intends to raise between $72.5m and $87m through an initial public offering (IPO) of 7.25 million shares valued between $10 and $12 a share.
Underwriters will be granted a 30-day option to purchase up to an additional 1.08 million shares to cover any over-allotment.
Naia Rare Diseases is set to raise funds for its clinical programme and to continue its first human trial in patients with short bowel movements through a series B financing round from Cedars-Sinai Medical Center.
Naia Rare Diseases is a biopharmaceutical company based in the US.